En los programas de acción nacionales que reciben asistencia, apoyo y coordinación internacionales, se debería incluir, cuando procediera, lo siguiente:

Antipsychotics

In 2015, Krka further increased its share among manufacturers of antipsychotics in the markets of Slovenia, Central, Eastern and South-Eastern Europe and strengthened its position as the leading generic manufacturer. In this field, Krka was among the leading companies in terms of absolute growth in sales. We sold most of our antipsychotics in Western Europe, where our sales saw the highest absolute growth.

Aryzalera* (aripiprazole) is our newest antipsychotic. We launched it in the European Union in 2014 and in 2015; it was

already available in more than 20 markets. We launched it as the first generic pharmaceutical company in Poland, the Czech Republic, Romania, and other markets of Central and South-Eastern Europe. We also

started marketing it in many Western European markets, including Spain, Italy and Portugal. Krka's aripiprazole is the leading generic aripiprazole in Europe, and Aryzalera* placed among the three leading Krka medicines in terms of absolute sales growth in 2015.

In terms of sales, Aryzalera* was followed by Zalasta* (olanzapine) and Kventiax* (quetiapine). Krka is among the leading generic producers of olanzapine in Europe. In the Russian Federation, Slovenia and some other markets, Zalasta* is the leading generic olanzapine. In 2015, we

launched Kventiax* prolonged-release tablets. The medicine is taken once daily, making treatment easier. We launched it in Germany, Spain, Poland, Hungary and other markets.

Krka also markets Zypsilan* (ziprasidone), the leading ziprasidone in the markets of Slovenia, Central, Eastern and South- Eastern Europe, and Torendo* (risperidone), the leading generic risperidone in the area. In Western Europe, Krka is among the leading generic manufacturers of risperidone orodispersible tablets, and in Germany among the leading generic manufacturers of ziprasidone.

Krka’s atypical antipsychotics

aripiprazole (Aryzalera/Aripipan/Arisppa/Zylaxera) olanzapine (Zalasta/Zolrix) quetiapine (Kventiax/Quentiax) risperidone (Torendo/Rorendo) ziprasidone (Zypsilan/Zypsila/Ypsila) Antidepressants

Krka has been the leading generic manufacturer of antidepressants in the markets of Slovenia, Central, Eastern and South-Eastern Europe for years. Last year, we increased our market share and therefore strengthened our leading position. In terms of quantities sold, Krka maintained its leading position among all manufacturers.

78

Krka became the leading generic manufacturer of duloxetine in Europe.

Krka is one of the leading generic manufacturers of memantine, donepezil and galantamine in Europe. of the leading generic manufacturers of memantine, donepezil and galantamine in Europe. .

Dulsevia* (duloxetine) is Krka's new antidepressant, which may also be used in the treatment of

painful diabetic neuropathy. We started marketing it in more than 20 countries, also in the biggest European markets, such as Great Britain, Italy, France and Spain. In more than 15 countries of Western, Central and South-Eastern Europe, Krka was the first generic pharmaceutical company to launch duloxetine. We became the leading generic manufacturer of duloxetine in Europe, and Dulsevia* ranked among the first three Krka's medicines in terms of absolute sales growth.

Elicea* (escitalopram) has been the leading generic escitalopram in the markets of Slovenia, Central, Eastern and South-

Eastern Europe for years. In 2015, it further strengthened its position by increasing market share. In Poland and Kazakhstan, it was the leader among all competitors, while in five other markets it placed as the first generic escitalopram, accounting for more than 20% of market share. In 2015, it was launched in Bulgaria.

With more than a 30% market share, Alventa* (venlafaxine) was the leading venlafaxine in Slovenia, Estonia, the Czech Republic and Slovakia, and took the leading place among generics in several other markets. Krka also markets it successfully in Western Europe, so last year Krka retained its place among the leading generic manufacturers of venlafaxine in Europe.

Our portfolio of antidepressants also contains Asentra (sertraline) and Mirzaten (mirtazapine). In the markets of Slovenia, Central, Eastern and South-Eastern Europe, Asentra increased its market share, strengthening the position of the leading generic sertraline, while mirtazapine retained its leading place among all competitors. We also started marketing it in Italy. Krka’s antidepressants duloxetine (Dulsevia/Duloxalta) escitalopram (Elicea/Ecytara/Escitalex/Anxila) venlafaxine (Alventa/Olwexya) sertraline (Asentra) mirtazapine (Mirzaten)

Medicines for the treatment of Alzheimer’s disease

Krka has been the leading generic producer of medicines for the treatment of Alzheimer's disease for years in Slovenia, and in Central, Eastern and South-Eastern Europe. Last year, we further strengthened the leading position by increasing our market share. Krka's portfolio comprises all four active ingredients used in the world for the treatment of Alzheimer's disease.

Marixino* (memantine) is the leading generic memantine in Portugal, the Czech Republic,

Slovenia and Lithuania. In 2015, it was launched in the Russian Federation, Serbia and Croatia. Krka is among the leading generic manufacturers of memantine in Europe.

The product range is supplemented by Galsya SR* (galantamine), Yasnal* (donepezil) and

Nimvastid (rivastigmine). Galsya SR* was the leading generic galantamine in Slovenia and

Romania, while in Slovakia it took the lead among all competitors. It also recorded strong sales in

Western Europe, where Krka placed as the leading generic manufacturer of galantamine. In that area, Krka also took the place among the leading generic manufacturers of donepezil. In 2015, as the only manufacturer, Krka launched Yasnal* orodispersible tablets also in Macedonia.

Krka’s medicines for the treatment of Alzheimer’s disease

memantine (Marixino/Memando/Maruxa/Memaxa/Mentixa/Maryzola) galantamine (Galsya SR/Galnora)

donepezil (Yasnal/Yasnoro) rivastigmine (Nimvastid)

79

Doreta is the leading fixed-dose

combination of tramadol and paracetamol in the markets of Slovenia, Central, Eastern and South-Eastern Europe.

Krka was the leading generic manufacturer of pregabalin in Western Europe. We are the leading generic

manufacturer of ropinirole, pramipexole and rasagiline in Europe.

Medicines for the treatment of Parkinson’s disease

For several successive years, Krka has been a leading generic producer of medicines for the treatment of Parkinson’s disease in the markets of Slovenia, Central, Eastern and South-Eastern Europe. In 2015, we

launched a new medicine rasagiline. It is Krka’s third medicine for the treatment of Parkinson's disease. We are the leading generic manufacturer of all three active substances in Europe.

Also in 2015, Rolpryna SR* (ropinirole) remained the leading generic ropinirole in many countries, including the Czech Republic, Portugal and Ireland. In Poland, Romania and Estonia, the medicine took the leading position among all ropiniroles. Also in 2015, Krka remained the leading generic producer of ropinirole in Europe.

Oprymea (pramipexole) was the leading generic pramipexole in Romania, Lithuania, and Hungary, holding more than 20%

of market share. It was also the leading generic pramipexole in Slovakia, Ireland and many other markets, while in Portugal, it took the leading place among all pramipexoles. In many markets, we started marketing new, greater strengths of pramipexole in prolonged-release tablets. Krka remained Europe’s leading supplier of pramipexole in prolonged-release tablet form.

In 2015, we added a new medicine, Rasagea* (rasagiline), for the treatment of Parkinson's disease to our portfolio. We started marketing it as one of the first generic medicine of its kind in Germany. In the future, we plan to market it in other markets. In 2015, Krka was the leading generic manufacturer of rasagiline in Western Europe.

Analgesics

Krka further strengthened the position of Doreta* (tramadol/paracetamol) fixed-dose combination in the markets of Slovenia, Central, Eastern and South-Eastern Europe. In comparison to 2014, its market share

increased and exceeded 30%. Sales were good also in Western Europe. We launched it in Germany, where we became the leading generic producer of this combination. We also ranked among the leading generic producers of this fixed-dose combination in Europe.

In 2014, we added Aclexa* (celecoxib), Krka's newest analgesic, to our portfolio of analgesics. In 2015, it remained the leading generic celecoxib in the markets of Slovenia, Central, Eastern and South-Eastern Europe. In Western Europe, too, Krka is among the leading generic producers of celecoxib. In Poland, the Czech Republic, Lithuania and Bulgaria, Aclexa* holds a market share of more than 30% and is ahead of all competitors. In 2015, it was also launched in Croatia and Kosovo.

Our portfolio of analgesics includes Naklofen duo (diclofenac) and Nalgesin* (naproxen), which is also available as a non- prescription product.

Other medicines for the treatment of diseases of the central nervous system

In 2014, we were the first generic producer in the European Union to launch Pragiola* (pregabalin) from the group of antiepileptic agents. Last year, marketing activities were extended to more than ten markets. As the first generic pharmaceutical company, we launched it in Slovenia, Austria, Ireland, Portugal, Croatia, and elsewhere. In Western Europe, Krka was the leading generic manufacturer of pregabalin in Slovenia and Austria, and remained the only generic manufacturer in certain other markets. In terms of absolute sales, Pragiola* was among the three leading Krka products.

80

Krka is the leading generic manufacturer of esomeprazole in Europe. In 2015, sales volume of proton pump inhibitors grew by 20%.

Medicines for the treatment of diseases of the alimentary tract and